Verrica Pharmaceuticals

VRCA

Market cap $87.5M

WEST CHESTER, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the TD Cowen 46th Annual Healthcare Conference in Boston.

WEST CHESTER, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the appointment of Chris Chapman as its Chief Commercial Officer.

WEST CHESTER, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical Co. Ltd.

Verrica Pharmaceuticals (VRCA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

LUV, VRCA, CVLT, FINW and SDVKY have been added to the Zacks Rank #1 (Strong Buy) List on February 2, 2026.

The mean of analysts' price targets for Verrica Pharmaceuticals (VRCA) points to a 97.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

– Common warts affects approximately 22 million patients in the United States alone, and there are no FDA approved prescription therapies for what is believed to be a multibillion-dollar market opportunity–

Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica's Board of Directors WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it has entered into a series of securities purchase agreements for a private investment in public equity (“PIPE”) financing, raising approximately $50 million in gross proceeds, before placement agent fees and offering expenses.

Verrica Pharmaceuticals Inc. ( VRCA ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jayson Rieger - President, CEO & Director John Kirby - Interim Chief Financial Officer Conference Call Participants Kevin Gardner Stacy Ku - TD Cowen, Research Division Yuchen Ding - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Brian Kemp Dolliver - Brookline Capital Markets, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals' Third Quarter 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

–   Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue –